LEVERAGE LONG - IPSEN | Market Closed - Euronext Paris 17:30:00 14/05/2024 BST | ||
| 38.56 EUR | +11.12% |
|
| Current month | +34.78% | ||
| 1 month | +65.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IPSEN
| Date | Price | Change |
|---|---|---|
| 14/05/24 | 38.56 | +11.12% |
| 13/05/24 | 34.7 | -2.12% |
| 10/05/24 | 35.45 | -0.06% |
| 09/05/24 | 35.47 | +14.83% |
| 08/05/24 | 30.89 | +4.89% |
Real-time Euronext Paris
Last update May 14, 2024 at 05:30 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | IPSEN |
| Issuer | 
Société Générale
|
| 4D79S | |
| ISIN | DE000SQ87XH7 |
| Date issued | 20/02/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50.87 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 94.38 € |
|---|---|
| Lowest since issue | 16.51 € |
| Spread | 1.3 € |
| Spread % | 3.32% |
Company Profile
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
-
Consensus: Ipsen
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.4
EUR
Average target price
126.2
EUR
Spread / Average Target
+3.91%
- Stock Market
- Certificates
- 4D79S Certificat
